PA
CPRX

PharVision Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

PharVision Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,329
Closed -$243K – 739
2025
Q3 		$243K Buy
+12,329
New +$254K 0.14% 353

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's CPRX Position: Q4 2025 in Review

PharVision Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 12,329 shares — an estimated $243K sold.

PharVision Advisers first reported a position in CPRX in Q3 2025 and held it in 1 quarter. The position peaked at $243K in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • PharVision Advisers reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 12,329 Catalyst Pharmaceutical shares in Q4 2025, an estimated $243K.
  • PharVision Advisers first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Catalyst Pharmaceutical position peaked at $243K in Q3 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.